AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04547504
Drug: Pembrolizumab and Chemotherapy drugs
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.
Trial: NCT06585319
Drug: Collagen-polyvinylpyrrolidone
RxNorm normalized name: Collagen-polyvinylpyrrolidone
DrugBank: Collagen-polyvinylpyrrolidone (DB16525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml intramuscular q24 h
Trial: NCT06585319
Drug: Pirfenidone 1200 mg
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1,200 mg of oral q12 h
Trial: NCT02963922
Drug: Liraglutide 3.0 mg
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (s.c., under the skin) once daily
Trial: NCT03554200
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of Care + Empagliflozin: 10 mg (tablets) once daily
Trial: NCT02784535
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine transporter inhibitor
Trial: NCT01839799
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
Trial: NCT01839799
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m2 IV over 30 minutes, day 1, 8, 15
Trial: NCT01116700
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
Trial: NCT02297945
Drug: metyrapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single arm study
Trial: NCT04412642
Drug: Methoxyflurane, MEOF
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Trial: NCT03735368
Drug: Dexmedetomidine Injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
Trial: NCT03735368
Drug: Pregabalin Oral Capsule
RxNorm normalized name: pregabalin Oral Capsule
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg pregabalin Oral Capsule
Trial: NCT01469975
Drug: OTSA101-DTPA-90Y level 1
RxNorm normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
Trial: NCT00585910
Drug: Atomoxetine and OROS Methylphenidate
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
Trial: NCT01469975
Drug: OTSA101-DTPA-90Y level 2
RxNorm normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
Trial: NCT01469975
Drug: OTSA101-DTPA-90Y level 3
RxNorm normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data.
Trial: NCT00580047
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg weekly
Trial: NCT02820298
Drug: Bexagliflozin
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin tablet, 20 mg
Trial: NCT02020551
Drug: Lidocaine Spray
RxNorm normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04632056
Drug: Beovu
RxNorm normalized name: Beovu
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
Trial: NCT01836809
Drug: nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
Trial: NCT01656187
Drug: Memantine 10 mg capsule
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Trial: NCT01656187
Drug: Memantine-matched Placebo capsule
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52).
Trial: NCT02879669
Drug: Pemetrexed/cisplatin (carboplatin)
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01339156
Drug: P3914
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Trial: NCT01436045
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
Trial: NCT01436045
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
Trial: NCT01825785
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by subcutaneous injection
Trial: NCT03167645
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substitution according to pre-specified dosage
Trial: NCT01837199
Drug: Metronidazole plus Amoxicillin
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
Trial: NCT00228813
Drug: Granulocyte Colony Stimulating Factor
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection
Trial: NCT01179659
Drug: Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose crossover BE study
Trial: NCT01836328
Drug: Parenteral /oral methadone ratio 1:2
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT01836328
Drug: Parenteral /oral methadone ratio 1:1.2
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions
Trial: NCT01285492
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg o.d.), delivered via Handihaler®
Trial: NCT01375777
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally once a day
Trial: NCT00839306
Drug: Rabeprazole ER
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg capsule, taken orally, once daily for 26 weeks.
Trial: NCT00839306
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Trial: NCT03362853
Drug: Nemonoxacin 500Mg Capsule
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose in a fasting state
Trial: NCT03362853
Drug: Moxifloxacin 400Mg Tablet
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive a single dose in a fasting state
Trial: NCT01121536
Drug: Armodafinil
RxNorm normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Armodafinil tablets, taken orally, once daily in the morning
Trial: NCT03362853
Drug: Nemonoxacin 750Mg Capsule
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose in a fasting state
Trial: NCT01918852
Drug: Teysuno
RxNorm normalized name: Teysuno
DrugBank: Gimeracil (DB09257)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01918852
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04768491
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Trial: NCT00003541
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00475878
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg escitalopram/day for 3 months
Trial: NCT00096993
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine was provided as a solution for infusion.
Trial: NCT00096993
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab was provided as a single-use formulation for infusion.
Trial: NCT02865811
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Please see Arms for description.
Trial: NCT03787680
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
Trial: NCT00003541
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003541
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01540084
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
Trial: NCT00003541
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003541
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00022880
Drug: Iodine-131 Anti-B1 Antibody
RxNorm normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00331799
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
Trial: NCT04591457
Drug: Insulin Glargine Sansulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
Trial: NCT00319670
Drug: MiraLax
RxNorm normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00357747
Drug: AEG35156
RxNorm normalized name: AEG35156
DrugBank: AEG35156 (DB06184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Trial: NCT00357747
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
Trial: NCT00473512
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
Trial: NCT00473512
Drug: Abiraterone acetate MTD
RxNorm normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate MTD orally for 12 cycles (28 day each).
Trial: NCT00473512
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
Trial: NCT04591457
Drug: Insulin Glargine Pen Injector [Lantus]
RxNorm normalized name: insulin glargine Pen Injector [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Trial: NCT01411176
Drug: Menthol
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL NPO-11 in a prefilled plastic syringe
Trial: NCT02665806
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal ciclesonide spray 200 µg once daily
Trial: NCT02665806
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate aqueous nasal spray 200 µg twice a day
Trial: NCT00203788
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Trial: NCT03236818
Drug: ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
Trial: NCT03245190
Drug: Chiauranib
RxNorm normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, orally once daily
Trial: NCT04065581
Drug: Acarbose/Metformin FDC(BAY81-9783)
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose: 50 mg acarbose/500 mg metformin tablet, oral
Trial: NCT04065581
Drug: Glucobay
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose: 50 mg tablet, oral
Trial: NCT04065581
Drug: Glucophage
RxNorm normalized name: Glucophage
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose: 500 mg tablet, oral
Trial: NCT03761225
Drug: Masitinib
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03761225
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03761225
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03172897
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
Trial: NCT03172897
Drug: Placebo (normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
Trial: NCT00026078
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00026078
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02454634
Drug: IDH1 peptide vaccine
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01192724
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg BID, for 3 months
Trial: NCT01192724
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg QD, for 1 year